HK1072947A1 - Immunological methods and compositions for the treatment of alzheimer's disease - Google Patents

Immunological methods and compositions for the treatment of alzheimer's disease

Info

Publication number
HK1072947A1
HK1072947A1 HK05105780.8A HK05105780A HK1072947A1 HK 1072947 A1 HK1072947 A1 HK 1072947A1 HK 05105780 A HK05105780 A HK 05105780A HK 1072947 A1 HK1072947 A1 HK 1072947A1
Authority
HK
Hong Kong
Prior art keywords
disease
alzheimer
compositions
treatment
immunological methods
Prior art date
Application number
HK05105780.8A
Other languages
English (en)
Inventor
George-Hyslop Peter St
Joanne Mclaurin
Original Assignee
Univ Toronto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Toronto filed Critical Univ Toronto
Publication of HK1072947A1 publication Critical patent/HK1072947A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
HK05105780.8A 2002-04-19 2005-07-08 Immunological methods and compositions for the treatment of alzheimer's disease HK1072947A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37391402P 2002-04-19 2002-04-19
PCT/CA2003/000502 WO2003089460A1 (fr) 2002-04-19 2003-04-07 Methodes et compositions immunologiques pour le traitement de la maladie d'alzheimer

Publications (1)

Publication Number Publication Date
HK1072947A1 true HK1072947A1 (en) 2005-09-16

Family

ID=29251102

Family Applications (2)

Application Number Title Priority Date Filing Date
HK05105780.8A HK1072947A1 (en) 2002-04-19 2005-07-08 Immunological methods and compositions for the treatment of alzheimer's disease
HK11113133.8A HK1158665A1 (zh) 2002-04-19 2005-07-08 用於治療阿爾茨海默氏病的免疫方法及組合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK11113133.8A HK1158665A1 (zh) 2002-04-19 2005-07-08 用於治療阿爾茨海默氏病的免疫方法及組合物

Country Status (18)

Country Link
US (5) US20030232758A1 (fr)
EP (2) EP2330113B1 (fr)
JP (3) JP4662719B2 (fr)
KR (1) KR100994748B1 (fr)
CN (1) CN100360555C (fr)
AT (1) ATE514707T1 (fr)
AU (1) AU2003218560B2 (fr)
CA (1) CA2481952C (fr)
ES (1) ES2368907T3 (fr)
HK (2) HK1072947A1 (fr)
IL (3) IL164643A0 (fr)
MX (1) MXPA04010255A (fr)
NO (2) NO335192B1 (fr)
NZ (1) NZ536064A (fr)
PL (1) PL209696B1 (fr)
SG (1) SG173214A1 (fr)
WO (1) WO2003089460A1 (fr)
ZA (1) ZA200408811B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2414772C (fr) 2000-07-07 2011-06-28 Jan Naslund Prevention et traitement de la maladie d'alzheimer
CA2504349A1 (fr) * 2001-11-02 2003-05-15 Diagenics International Corporation Methodes et compositions d'anticorps monoclonaux specifiques des proteines beta-amyloides
US20050106626A1 (en) * 2002-10-20 2005-05-19 George Pieczenik Ligand binding of amyloid peptide protein epitope
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
US8193250B2 (en) * 2004-10-22 2012-06-05 Mount Sinai School Of Medicine Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system
EP1820019A4 (fr) * 2004-11-12 2008-05-14 Pfizer Methode permettant de mesurer des peptides beta-amyloides
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
CA2632822C (fr) 2005-12-12 2018-08-28 Ruth Greferath Anticorps monoclonaux specifiques beta 1-42 ayant des proprietes therapeutiques
US8034353B2 (en) 2006-02-22 2011-10-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Peptide vaccine for inducing the production of anti-amyloid β-peptide antibody
DE602007011415D1 (de) 2006-03-23 2011-02-03 Bioartic Neuroscience Ab Verbesserte protofibrilselektive antikörper und deren verwendung
DE112007001030T5 (de) * 2006-04-28 2009-02-26 Kagoshima University Amyloid-ß-Fibrillogenese-inhibierendes Peptid
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2094730A4 (fr) * 2006-12-07 2010-08-04 Mayo Foundation Procédés et matériaux associés à des anticorps anti-amyloïdes
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
EP2481408A3 (fr) 2007-03-01 2013-01-09 Probiodrug AG Nouvelle utilisation d'inhibiteurs glutaminyle cyclase
EP2865670B1 (fr) 2007-04-18 2017-01-11 Probiodrug AG Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
US8815794B2 (en) * 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
US8912145B2 (en) 2008-11-28 2014-12-16 Hokko Chemical Industry Co., Ltd. Vaccine composition for prophylaxis and/or therapy of Alzheimer's disease
EP2365071B1 (fr) * 2008-11-28 2016-04-06 Hokko Chemical Industry Co., Ltd. Plante de soja transformée qui stocke un vaccin, et utilisation de celle-ci
CN101797493B (zh) * 2009-02-06 2014-05-21 上海抗体药物国家工程研究中心有限公司 一种在反应釜中制备亲和层析介质的方法
CN101486768B (zh) * 2009-02-25 2012-05-30 吉林大学 一种用于治疗阿尔茨海默氏病的抗原蛋白及蛋白基因
WO2010124028A2 (fr) * 2009-04-21 2010-10-28 Vasylyev Sergiy V Systèmes de collecte de lumière et d'éclairage à guide d'onde plan
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
EP2545047B9 (fr) 2010-03-10 2015-06-10 Probiodrug AG Inhibiteurs hétérocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5)
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
EP2560953B1 (fr) 2010-04-21 2016-01-06 Probiodrug AG Inhibiteurs de glutaminyl cyclase
CA2806909C (fr) 2010-07-30 2019-12-17 Ac Immune S.A. Anticorps humanises surs et fonctionnels
EP2603524A1 (fr) 2010-08-14 2013-06-19 AbbVie Inc. Protéines de liaison bêta-amyloïdes
US20120321694A1 (en) * 2010-10-27 2012-12-20 Daniel Larocque Compositions and uses
JP6050264B2 (ja) 2011-03-16 2016-12-21 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
DE102011057019A1 (de) * 2011-12-23 2013-06-27 Forschungszentrum Jülich GmbH Standard zur Quantifizierung von pathogenen Aggregaten aus körpereigenen Proteinen
JP6130401B2 (ja) * 2012-01-20 2017-05-17 アンナプラガダ，アナンス 医学画像を客観的に特徴付けるための方法および組成物
US9534048B2 (en) * 2012-08-24 2017-01-03 University Health Network Antibodies to TTR and methods of use
WO2014041069A1 (fr) * 2012-09-12 2014-03-20 Neurimmune Holding Ag Anticorps spécifiques du polypeptide amyloïde des îlots humains (hiapp) et leurs utilisations
DK2906597T3 (da) * 2012-10-15 2020-07-13 Medimmune Ltd Antistoffer mod beta-amyloid
WO2015017280A1 (fr) 2013-07-28 2015-02-05 Qantu Therapeutics, Inc. Formulation de vaccins induisant une réponse immunitaire de type th2
FI3137094T3 (fi) * 2014-04-29 2023-03-20 Advantage Therapeutics Inc Alzheimerin taudin (ad) hoitaminen ja ehkäiseminen
PL3166970T3 (pl) 2014-07-10 2021-09-13 Bioarctic Ab Ulepszone przeciwciała wiążące protofibryle a-beta
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2017098516A1 (fr) * 2015-12-10 2017-06-15 The National Institute for Biotechnology in the Negev Ltd. Variantes du domaine inhibiteur du précurseur de la bêta-protéine amyloïde
NZ754020A (en) * 2016-11-25 2022-11-25 Genuv Inc Composition for promoting differentiation of and protecting neural stem cells and method for inducing neural regeneration using same
JOP20200041A1 (ar) 2017-08-22 2020-02-20 Biogen Ma Inc تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
PL3461819T3 (pl) 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
CR20240219A (es) 2017-10-25 2024-07-09 Ac Immune Sa COMPOSICIONES DE PÉPTIDOS TAU FOSFORILADOS Y SUS USOS (DIVISIONAL Exp. 2020-0219)
EP3793583A4 (fr) * 2018-05-18 2022-03-09 Université Laval Utilisation d'un agoniste de nod2 pour le traitement, la prophylaxie et/ou le retardement de l'apparition de la sclérose en plaques et de la maladie d'alzheimer
CA3129252A1 (fr) * 2019-02-08 2020-08-13 Ac Immune S.A. Methode d'administration sure d'un vaccin de peptide de tau phosphoryle
US20220119468A1 (en) * 2019-02-22 2022-04-21 Loyola Marymount University Amyloid peptide variants
AU2020262899A1 (en) 2019-04-24 2021-11-18 Ac Immune S.A. Heterologous administration of tau vaccines
TW202144387A (zh) * 2020-02-11 2021-12-01 美商聯合生物醫學公司 針對胰島澱粉樣多肽（iapp）的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑
CN115925987A (zh) * 2022-02-28 2023-04-07 安域生物科技(杭州)有限公司 基于β-淀粉样蛋白修饰的抗原多肽及其应用
CN115786260B (zh) * 2022-12-26 2024-08-20 海南大学 Aβ42-hIAPP共寡聚化物诱导的AD脑类器官病理模型方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666829A (en) * 1985-05-15 1987-05-19 University Of California Polypeptide marker for Alzheimer's disease and its use for diagnosis
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5840294A (en) 1993-03-29 1998-11-24 Queen's University At Kingston Method for treating amyloidosis
ES2180576T3 (es) * 1993-04-27 2003-02-16 United Biomedical Inc Construcciones peptidicas de lhrh inmunogenicas y estimuladores de inmunidad universales sinteticos para vacunas.
US5759551A (en) 1993-04-27 1998-06-02 United Biomedical, Inc. Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CA2242851A1 (fr) 1995-08-17 1997-02-27 The Ontario Cancer Institute Methode de controle de l'assemblage des fibrilles de proteine
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
DE60144164D1 (de) 2000-06-20 2011-04-14 Univ Toronto Transgenes Tiermodel für neurodegenerative Krankheiten
US6310810B1 (en) 2000-07-14 2001-10-30 Raj Kumar Jain High-speed sense amplifier
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide

Also Published As

Publication number Publication date
US20120315321A1 (en) 2012-12-13
WO2003089460A1 (fr) 2003-10-30
AU2003218560B2 (en) 2009-09-03
US20160297876A1 (en) 2016-10-13
CN100360555C (zh) 2008-01-09
ES2368907T3 (es) 2011-11-23
IL164643A (en) 2011-11-30
CN1646559A (zh) 2005-07-27
US20140212481A1 (en) 2014-07-31
EP2330113A1 (fr) 2011-06-08
CA2481952A1 (fr) 2003-10-30
JP4662719B2 (ja) 2011-03-30
PL209696B1 (pl) 2011-10-31
US20030232758A1 (en) 2003-12-18
JP2006505502A (ja) 2006-02-16
KR20040108747A (ko) 2004-12-24
EP2330113B1 (fr) 2016-06-29
JP2010065046A (ja) 2010-03-25
NO335192B1 (no) 2014-10-20
EP1497321A1 (fr) 2005-01-19
NO20131483L (no) 2005-01-18
NO20045021L (no) 2005-01-18
HK1158665A1 (zh) 2012-07-20
IL196532A0 (en) 2009-09-22
IL164643A0 (en) 2005-12-18
ZA200408811B (en) 2005-07-27
EP1497321B1 (fr) 2011-06-29
JP2013075898A (ja) 2013-04-25
IL196532A (en) 2013-02-28
PL373450A1 (en) 2005-08-22
US20090041771A1 (en) 2009-02-12
KR100994748B1 (ko) 2010-11-17
AU2003218560A1 (en) 2003-11-03
MXPA04010255A (es) 2008-03-04
JP5345920B2 (ja) 2013-11-20
NZ536064A (en) 2008-06-30
SG173214A1 (en) 2011-08-29
ATE514707T1 (de) 2011-07-15
CA2481952C (fr) 2013-10-29

Similar Documents

Publication Publication Date Title
HK1072947A1 (en) Immunological methods and compositions for the treatment of alzheimer's disease
MXPA05003621A (es) Metodos de tratamiento de la enfermedad de alzheimer usando anticuerpos dirigidos contra el peptido beta amiloide y composiciones de los mismos.
TWI263503B (en) Composition comprising an antibody or a polypeptide preparation as the active agent for the prevention and treatment of amyloidogenic disease and method for in vitro screening of the antibody
MXPA05008156A (es) Inmunizacion activa para generar anticuerpos para beta-a soluble.
BG104562A (en) Composition and method for prevention and treatment of amyloidogenic disease
TW200617023A (en) Antibodies directed against amyloid-beta peptide and methods using same
HUP0204074A2 (hu) Abéta peptidet kiválasztó humanizált ellenanyagok
WO2005018424A3 (fr) Anticorps specifiques de la proteine amyloide fibrillaire et procedure permettant de detecter des depots de proteines amyloides fibrillaires
ATE535252T1 (de) Peptid-konjugat-zusammensetzungen und -verfahren zur prävention und behandlung von alzheimer- krankheit
PL2087904T3 (pl) Zastosowanie terapeutyczne peptydów pochodzących z białek BcL-XL u pacjentów z rakiem
TW200732348A (en) Monoclonal antibody
ZA200308767B (en) Immunogenic peptide composition for the prevention and treatment of alzheimers disease
HUP0302589A2 (hu) A béta-amiloid peptidet felismerő humanizált ellenanyagok
ATE397068T1 (de) Antigene meningokokken peptide
MXPA03011521A (es) Aminadioles para tratamiento de enfermedad de alzheimer.
DK1553985T3 (da) Biphenyler som billeddannelsesmiddel i forbindelse med Alzheimers sygdom
MXPA04000337A (es) Amindioles para tratamiento de enfermedad de alzheimer.
RU2353389C2 (ru) Способы лечения болезни альцгеймера с использованием антител, направленных против пептида амилоида-бета, и их композиций
AP1638A (en) Peptide mimics of conserved gonococcal epitopes and methods and compositions using them.
WO2002102849A3 (fr) Nouvelle proteine associee au cancer

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160407